Unknown cellular target

The term "Unknown cellular target" is a placeholder used in pharmacology and drug discovery to denote a situation where a compound exhibits a biological or therapeutic effect, but the specific molecular entity (such as a protein, enzyme, or receptor) responsible for that effect has not been identified [1, 5]. This is a common occurrence in phenotypic drug discovery, where molecules are screened for their ability to alter a cellular phenotype without prior knowledge of the target [7]. Identifying the target, a process known as target deconvolution, is a critical step in drug development to understand the mechanism of action, optimize potency, and predict potential side effects [2, 8]. Until the target is characterized, the therapeutic mechanism remains speculative, and the development process often involves techniques like affinity chromatography, genetic screening, or proteomics to identify the binding partner [1, 2]. Because this is a placeholder, it does not possess a specific biological function or disease role; rather, it represents a gap in knowledge regarding the molecular basis of a drug's activity [5, 6]. Consequently, drugs associated with an unknown target are often studied for their phenotypic outcomes rather than their molecular interactions [4, 7]. This classification is frequently seen in early-stage research or for natural products with complex polypharmacology [8]. Regulatory agencies typically require target identification for modern drug approval to ensure safety and efficacy [2].

The mechanism of action is currently undefined at the molecular level; compounds interact with an unidentified cellular component to produce a phenotypic response [1, 5].